Will There Be a Role for a Short-Acting Biosimilar Erythropoiesis-Stimulating Agent in US Nephrology Practice?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Will There Be a Role for a Short-Acting Biosimilar Erythropoiesis-Stimulating Agent in US Nephrology Practice?

Published:2019-09 Issue:9 Volume:4 Page:1199-1202
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Wish Jay B.

Publisher

Elsevier BV

Subject

Nephrology

Reference10 articles.

1. The approval process for biosimilar erythropoiesis stimulating agents;Wish;Clin J Am Soc Nephrol,2014

2. The economic implications of biosimilars;Singh;Am J Manag Care,2015

3. The immunogenicity of biosimilar recombinant human erythropoietin (r-HuEpo) administered by subcutaneous injection for the treatment of anemia in patients with chronic kidney disease;Praditpornsilpa;Kidney Int,2011

4. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes;Boven;Kidney Int,2005

5. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity;Seidl;Pharm Res,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP